Literature DB >> 1565364

Pelvic exenteration in the elderly patient.

C M Matthews1, M Morris, T W Burke, D M Gershenson, J T Wharton, F N Rutledge.   

Abstract

Advanced age is frequently considered a contraindication to radical exenterative surgery. We reviewed the outcomes of 63 patients age 65 years or older who underwent pelvic exenteration between 1960-1991 at The University of Texas M. D. Anderson Cancer Center. Sixty-three percent had preexisting medical illnesses. Major or potentially life-threatening complications were noted in 38% of the patients. An additional 38% experienced minor complications. Sixty percent experienced one or more infectious complications, including pyelonephritis, wound infection, sepsis, and flap necrosis. When both major and minor complications were considered, infectious morbidity was the single largest category. Although they are not life-threatening, nonspecific infectious morbidity and transient confusion were the most frequent individual complications, occurring in 26 and 24% of patients, respectively. Twenty-four percent of the patients experienced no complications. Thirty-four percent of the postoperative survivors suffered late major morbidity. Operative mortality was 11%; multisystem failure was the most frequent cause of death. After a mean follow-up of 4 years, 22 patients were alive with no clinical evidence of disease. Twenty-one patients died of recurrent disease, with a median time to recurrence of 9.6 months. The 5-year survival rate for the group was 46%. In comparison, 363 patients younger than age 65 who underwent exenteration during the same period experienced an operative mortality rate of 8.5% and a 5-year survival rate of 45%, neither of which were significantly different from the rates found for the older group (P = .51 and .52, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1565364

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  7 in total

1.  Pelvic exenteration in gynecologic oncology: a single institution study over 20 years.

Authors:  T Benn; R A Brooks; Q Zhang; M A Powell; P H Thaker; D G Mutch; I Zighelboim
Journal:  Gynecol Oncol       Date:  2011-03-27       Impact factor: 5.482

Review 2.  The role of palliative surgery in gynecologic cancer cases.

Authors:  Joanie Mayer Hope; Bhavana Pothuri
Journal:  Oncologist       Date:  2013-01-08

3.  [Microsurgical reconstruction of the pelvic floor after pelvic exenteration. Reduced morbidity and improved quality of life by an interdisciplinary concept].

Authors:  N M Stechl; S Baumeister; K Grimm; T W Kraus; H Bockhorn; K E Exner
Journal:  Chirurg       Date:  2011-07       Impact factor: 0.955

4.  Elderly Patients Have Better Quality of Life but Worse Survival Following Pelvic Exenteration: A 25-Year Single-Center Experience.

Authors:  Raha Alahmadi; Daniel Steffens; Michael J Solomon; Peter J Lee; Kirk K S Austin; Cherry E Koh
Journal:  Ann Surg Oncol       Date:  2021-03-09       Impact factor: 5.344

5.  Pelvic exenteration: impact of age on surgical and oncologic outcomes.

Authors:  Marilyn Huang; David A Iglesias; Shannon N Westin; Bryan Fellman; Diana Urbauer; Kathleen M Schmeler; Michael Frumovitz; Pedro T Ramirez; Pamela T Soliman
Journal:  Gynecol Oncol       Date:  2013-11-18       Impact factor: 5.482

6.  Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer.

Authors:  Carlos Lopez-Graniel; Rigoberto Dolores; Lucely Cetina; Aaron Gonzalez; David Cantu; Jose Chanona; Jesus Uribe; Myrna Candelaria; Rocio Brom; Jaime de la Garza; Alfonso Duenas-Gonzalez
Journal:  BMC Cancer       Date:  2005-09-19       Impact factor: 4.430

7.  Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy.

Authors:  T Ota; N Takeshima; T Tabata; K Hasumi; K Takizawa
Journal:  Br J Cancer       Date:  2008-10-21       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.